Treatment of postpartum hemorrhage with misoprostol

@article{Blum2007TreatmentOP,
  title={Treatment of postpartum hemorrhage with misoprostol},
  author={Jennifer Blum and Zarko Alfirevic and Gijs Walraven and A D Weeks and Beverly Winikoff},
  journal={International Journal of Gynecology \& Obstetrics},
  year={2007},
  volume={99}
}
A literature review was conducted to determine whether misoprostol is an effective treatment for postpartum hemorrhage (PPH) and in what dose. All English language articles published before March 2007 reporting on misoprostol for treatment of PPH were reviewed. Unpublished data previously presented at international scientific meetings were also included in the review. Little evidence exists in support of misoprostol for treatment of postpartum hemorrhage (PPH). Nonetheless, PPH remains a major… Expand
Efficacy of misoprostol for the treatment of postpartum hemorrhage: current knowledge and implications for health care planning
TLDR
Clinical guidelines and treatment protocols should be updated to reflect the current knowledge on the efficacy of misoprostol for the treatment of PPH with 800 μg sublingually, as well as the beneficial adjunctive role of misOProstol to conventional uterotonics. Expand
Misoprostol for the prevention and treatment of postpartum haemorrhage.
TLDR
There is very limited evidence for the effectiveness of misoprostol, the lowest effective dose and the magnitude of adverse effects, both direct and indirect; the need for further research is a matter of great urgency. Expand
Efficacy of Rectal Misorpostol when Combined with Standard Oxytocin to Treat Postpartum Hemorrhage
TLDR
Misoprostol is an effective treatment for postpartum hemorrhage in Pakistan and there was a significant difference in blood loss of >1000 ml (p 0.05). Expand
Misoprostol for prevention and treatment of postpartum haemorrhage: A systematic review.
TLDR
The use of misoprostol was not associated with any significant reduction in the incidence of PPH, and specialised investigations of its dose and routes of administration for clinically significant effects and acceptable side effects are warranted. Expand
Postpartum misoprostol for preventing maternal mortality and morbidity.
TLDR
To review maternal deaths and severe morbidity in all randomised trials of misoprostol for prevention or treatment of PPH, a large number of women will be needed to obtain robust estimates of maternal mortality, and cluster- and quasi-randomised trials are planned. Expand
Comparison effect of intravenous tranexamic acid and misoprostol for postpartum haemorrhage
TLDR
It is stated that Misoprostol has no specific preferences to TXA, but more studies with greater population are needed, as active prevention of haemorrhage with an uterotonic or other new drugs leads to a decrease in postpartum vaginal haemorsrhage. Expand
Sublingual misoprostol and hyperpyrexia: case report with temperature curve
TLDR
A 30 year old Cameroonian female gravida 1 para 1 who had a vaginal delivery at 40 weeks of gestation complicated by primary postpartum haemorrhage (PPH) was managed by sublingual misoprostol that induced shivering and hyperpyrexia managed successfully with paracetamol and cooling. Expand
Obstetric use of misoprostol: innovations, evidence, controversy and global health perspectives
TLDR
40 papers document a series of randomized trials and systematic reviews showing that only in extremely small dosages was the safety of misoprostol similar to that of alternative prostaglandins registered for use for labour induction and the prevention and treatment of haemorrhage after childbirth. Expand
A Relative Bioavailability Study of Two Misoprostol Formulations Following a Single Oral or Sublingual Administration
TLDR
The relative bioavailability between Angusta and Cytotec could not be confirmed as being equal at the 25 µg or 50 µg level because the 90% CI-values when comparing the ratios for AUC, AUC(0−t), and Cmax were wider than accepted. Expand
Misoprostol as an adjunct to standard uterotonics for treatment of post-partum haemorrhage: a multicentre, double-blind randomised trial
TLDR
Findings from this study do not support clinical use of 600 microg sublingual misoprostol in addition to standard injectable uterotonics for treatment of post-partum haemorrhage. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 36 REFERENCES
Management of severe postpartum hemorrhage with misoprostol
TLDR
Among the 18 cases of severe atonic postpartum hemorrhage not responding to oxytocin methylergometrine and enzaprost 16 cases responded promptly to misoprostol, indicating that rectal misop frostol is an effective line of treatment in cases of atonic hemorrhage refractory to other drugs. Expand
Misoprostol in addition to routine treatment of postpartum hemorrhage: A hospital-based randomized-controlled trial in Karachi, Pakistan
TLDR
A 600 mcg dose of misoprostol given sublingually shows promise as an adjunct treatment for PPH and its use should continue to be explored for its life-saving potential in the care of women experiencing PPH. Expand
[Rectal administration of misoprostol for delivery induced hemorrhage. Preliminary study].
TLDR
Preliminary findings are encouraging and suggest that further investigations would be useful to assess the beneficial effect of misoprostol by rectal administration for patients with severe delivery-induced hemorrhage due to uterine atony. Expand
Misoprostol to treat postpartum haemorrhage: a systematic review
TLDR
The aim of this review was to determine the route of administration and dosage of misoprostol most likely to be effective in the treatment of PPH and identify randomised controlled trials that compared misop frostol with any appropriate control groups. Expand
Misoprostol in the treatment of postpartum haemorrhage in addition to routine management: a placebo randomised controlled trial
TLDR
This randomised controlled trial compared misoprostol 600 μg (200 μg orally and 400 μg sublingually) with placebo in the treatment of postpartum haemorrhage in addition to routine treatment. Expand
Misoprostol for treating postpartum haemorrhage: a randomized controlled trial [ISRCTN72263357]
TLDR
This study could not confirm the dramatic effect of misoprostol reported in several unblinded studies, but the results do not exclude a clinically important effect. Expand
Rectally administered misoprostol for the treatment of postpartum hemorrhage unresponsive to oxytocin and ergometrine: a descriptive study.
TLDR
Rectally administered misoprostol appears to be an effective treatment for postpartum hemorrhage unresponsive to oxytocin and ergometrine; therefore, it might be an alternative to parenteral prostaglandins or at least minimize the number of women requiring this invasive treatment. Expand
Systematic Review of Randomized Controlled Trials of Misoprostol to Prevent Postpartum Hemorrhage
TLDR
Injectable Oxytocin or oxytocinergot preparations are more effective than misoprostol as part of the active management of the third stage of labor. Expand
Oral misoprostol in preventing postpartum haemorrhage in resource-poor communities: a randomised controlled trial
TLDR
Oral misoprostol was associated with significant decreases in the rate of acute postpartum haemorrhage and mean blood loss, which makes it a good option in resource-poor settings. Expand
Control of Postpartum Uterine Atony by Intramyometrial Prostaglandin
TLDR
Five patients with severe postpartum hemorrhage due to uterine atony and unresponsive to oxytocin, ergonovine, and massage were treated with intramyomaterial injection of prostaglandin, and three responded successfully with an increase in uterine tone and cessation of uterine hemorrhage, thus obviating the need for hysterectomy. Expand
...
1
2
3
4
...